Group One Trading’s INmune Bio INMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$804 Buy
493
+105
+27% +$145 ﹤0.01% 7219
2026
Q1
$438 Buy
+388
New +$553 ﹤0.01% 7332
2025
Q4
Sell
-38,584
Closed -$68.8K 8614
2025
Q3
$79.9K Buy
+38,584
New +$88.3K ﹤0.01% 5553
2025
Q2
Sell
-15,526
Closed -$114K 8256
2025
Q1
$121K Buy
+15,526
New +$123K ﹤0.01% 4447
2024
Q1
Sell
-2,375
Closed -$28.7K 7463
2023
Q4
$26.7K Sell
2,375
-43,614
-95% -$366K ﹤0.01% 5523
2023
Q3
$315K Buy
45,989
+23,351
+103% +$194K ﹤0.01% 3390
2023
Q2
$206K Buy
22,638
+13,602
+151% +$109K ﹤0.01% 3899
2023
Q1
$58.4K Buy
9,036
+7,724
+589% +$62.2K ﹤0.01% 4740
2022
Q4
$8.32K Sell
1,312
-34,844
-96% -$247K ﹤0.01% 6101
2022
Q3
$224K Buy
36,156
+2,683
+8% +$23.6K ﹤0.01% 4025
2022
Q2
$296K Buy
33,473
+9,519
+40% +$70.8K ﹤0.01% 3917
2022
Q1
$202K Sell
23,954
-6,873
-22% -$61.7K ﹤0.01% 4788
2021
Q4
$314K Buy
30,827
+13,021
+73% +$193K ﹤0.01% 4618
2021
Q3
$346K Buy
17,806
+13,130
+281% +$254K ﹤0.01% 4593
2021
Q2
$82K Buy
+4,676
New +$63K ﹤0.01% 6150

Other funds holding INMB

Group One Trading's INMB Position: Q2 2026 in Review

Group One Trading increased its INmune Bio (INMB) stake by 27% in Q2 2026, buying an estimated $145 and bringing the position to 493 shares worth $804. The position accounts for ﹤0.01% of the portfolio, ranked #7219.

Group One Trading first reported a position in INMB in Q2 2021 and has held it in 15 quarters since. The position peaked at $346K in Q3 2021. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Group One Trading held 493 shares of INmune Bio worth $804 as of Q2 2026.
  • Group One Trading bought 105 INmune Bio shares in Q2 2026, an estimated $145.
  • INmune Bio made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7219 holding.
  • Group One Trading first reported a position in INmune Bio in Q2 2021 and has held it in 15 quarters since.
  • Group One Trading's INmune Bio position peaked at $346K in Q3 2021.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.